Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository.
Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, Dagher A, Das S, Desautels A, Drouin-Ouellet J, Durcan T, Gagnon JF, Genge A, Karamchandani J, Lafontaine AL, Sun SLW, Langlois M, Levesque M, Melmed C, Panisset M, Parent M, Poline JB, Postuma RB, Pourcher E, Rouleau GA, Sharp M, Monchi O, Dupré N, Fon EA. Gan-Or Z, et al. Among authors: genge a. J Parkinsons Dis. 2020;10(1):301-313. doi: 10.3233/JPD-191775. J Parkinsons Dis. 2020. PMID: 31868683 Free PMC article.
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
Genge A, Cedarbaum JM, Shefner J, Chio A, Al-Chalabi A, Van Damme P, McDermott C, Glass J, Berry J, van Eijk RPA, Fournier C, Grosskreutz J, Andrews J, Bertone V, Bunte TM, Couillard M, Cummings C, Kittle G, Polzer J, Salmon K, Straub C, van den Berg LH. Genge A, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):382-387. doi: 10.1080/21678421.2024.2320880. Epub 2024 Feb 23. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38396337 Free article.
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Butzner M, Chiò A, Andrews JA, Genge A, Hughes DA, Jackson CE, Lechtzin N, Miller TM, Shefner JM. Gebrehiwet P, et al. Among authors: genge a. J Med Econ. 2023 Jan-Dec;26(1):488-493. doi: 10.1080/13696998.2023.2192588. J Med Econ. 2023. PMID: 36930042 Free article. Clinical Trial.
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Genge A, Pattee GL, Sobue G, Aoki M, Yoshino H, Couratier P, Lunetta C, Petri S, Selness D, Bidani S, Hirai M, Sakata T, Salah A, Apple S, Wamil A, Kalin A, Jackson CE. Genge A, et al. Muscle Nerve. 2023 Feb;67(2):124-129. doi: 10.1002/mus.27768. Epub 2022 Dec 28. Muscle Nerve. 2023. PMID: 36504406 Free PMC article. Clinical Trial.
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. Shefner JM, et al. Among authors: genge a. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):523-534. doi: 10.1080/21678421.2023.2216223. Epub 2023 May 30. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37254449 Clinical Trial.
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Chiò A, Andrews JA, Genge A, Jackson CE, Lechtzin N, Miller TM, Shefner JM. Gebrehiwet P, et al. Among authors: genge a. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):304-310. doi: 10.1080/21678421.2022.2154678. Epub 2022 Dec 12. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36503310 Clinical Trial.
The C-BIG Repository: an Institution-Level Open Science Platform.
Das S, Abou-Haidar R, Rabalais H, Sun SDLW, Rosli Z, Chatpar K, Boivin MN, Tabatabaei M, Rogers C, Legault M, Lo D, Degroot C, Dagher A, Dyke SOM, Durcan TM, Seyller A, Doyon J, Poupon V, Fon EA, Genge A, Rouleau GA, Karamchandani J, Evans AC. Das S, et al. Among authors: genge a. Neuroinformatics. 2022 Jan;20(1):139-153. doi: 10.1007/s12021-021-09516-9. Epub 2021 May 18. Neuroinformatics. 2022. PMID: 34003431 Free PMC article.
CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS.
Picher-Martel V, Magnussen C, Blais M, Bubela T, Das S, Dionne A, Evans AC, Genge A, Greiner R, Iturria-Medina Y, Johnston W, Jones K, Kaneb H, Karamchandani J, Moradipoor S, Robertson J, Rogaeva E, Taylor DM, Vande Velde C, Yunusova Y, Zinman L, Kalra S, Dupré N. Picher-Martel V, et al. Among authors: genge a. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Feb;24(1-2):33-39. doi: 10.1080/21678421.2022.2041668. Epub 2022 Feb 23. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 35195049
128 results